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ABSTRACT
Impaired glucose metabolism can occur in patient with chronic liver disease, either it is impaired glucose 
tolerance or diabetes mellitus (DM). DM due to liver cirrhosis is known as hepatogenous diabetes (HD). HD 
is different from type 2 DM in clinical signs and management.
A 33-year-old female came with chief complaint of fatigue since three days before admission. Patient also 
complained of nausea, vomiting, and increased abdominal circumference since one year ago. Patient was 
diagnosed with DM two months ago. From physical examination, anemic and ascites without signs of cirrhosis 
were obtained. Laboratory test showed mild anemia with hemoglobin levels 6.5 g/dL, elevated serum bilirubin 
and liver enzymes, decreased serum albumin, prolonged prothrombin time and elevated random blood glucose. 
Serologic test showed chronic hepatitis B with HBV DNA 1.61 x 104 copy/mL. The abdominal ultrasound result 
showed liver cirrhosis with ascites.
The patient was diagnosed with hepatogenous diabetes in liver cirrhosis due to chronic hepatitis B infection 
and anemia of chronic disease. The management of this patient was quite complex especially in administration 
of oral antidiabetic agent which could affect the liver function.
Keywords: hepatogenous diabetes, liver cirrhosis, diabetes mellitus, chronic hepatitis B infection
ABSTRAK
Pada penderita penyakit hati menahun dapat terjadi gangguan metabolisme gula, yaitu dari toleransi glukosa 
terganggu sampai diabetes melitus (DM). DM yang terjadi akibat komplikasi dari sirosis hati dikenal sebagai 
hepatogeneous diabetes (HD) atau DM tipe sirosis. DM tipe sirosis berbeda dengan DM tipe 2 baik dalam 
gejala klinis maupun tatalaksananya.
Seorang perempuan usia 33 tahun datang dengan keluhan utama badan lemas sejak tiga hari sebelum masuk 
rumah sakit. Pasien juga mengeluh mual, muntah, dan pembesaran perut sejak satu tahun yang lalu. Pasien 
diketahui menderita DM sejak dua bulan yang lalu. Pemeriksaan fisik menunjukkan keadaan anemis dan adanya 
asites tanpa disertai tanda-tanda sirosis. Pemeriksaan laboratorium menunjukkan anemia ringan dengan kadar 
hemoglobin 6,5 g/dL, peningkatan serum bilirubin dan enzim hati, penurunan kadar albumin, pemanjangan 
protrombin time dan peningkatan gula darah sewaktu. Tes serologis menunjukkan hepatitis B kronik dengan 
HBV DNA 1.61 x 104 copy/mL. Kesan sirosis hati dengan asites didapatkan pada hasil ultrasonografi abdomen.
Diagnosa kerja pasien ini adalah DM tipe sirosis pada sirosis hati akibat hepatitis B kronik dan anemia 
akibat penyakit kronik. Penatalaksanaan DM tipe sirosis cukup kompleks terutama dalam hal pemberian obat 
antidiabetes oral karena akan mempengaruhi fungsi hati.
Kata kunci: DM tipe sirosis, sirosis hati, diabetes melitus, infeksi hepatitis B kronik
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INTRODUCTION 
Hepatitis B is an infection of the liver caused by 
hepatitis B virus (HBV). Most adults usually suffer 
from hepatitis B infection and permanently recover. For 
some patients, predominantly in early age patient such 
as newborn or children, hepatitis B virus will remain 
in their body and may even progress into chronic liver 
infection.1 Chronic hepatitis B infection can develop 
from asymptomatic, symptomatic, liver cirrhosis, or 
hepatocellular carcinoma.2 
About 20-40% chronic liver disease will progress 
into cirrhosis in approximately 15 years later.3 Patient 
with cirrhosis can suffer resistance of insulin, from 
impaired glucose tolerance to diabetes mellitus 
(DM).4.5  DM originated from liver cirrhosis is known 
as hepatogenous diabetes (HD). HD is more likely in 
patients without risk factors for type 2 DM and the 
appearance of new onset hyperglycemia in the setting 
of cirrhosis.6 However there has been no descriptive 
studies done to determine the prevalence of HD. 
Clinical progression of HD is different from that 
of type 2 DM (T2DM), where HD is less frequently 
associated with microangiopathy.7 There is no definitive 
test to differentiate T2DM with liver dysfunction from 
HD.4  Study by Kim et al suggested the use of 2 hours 
post prandial (2hPP) glucose/fasting plasma glucose 
(FPG) and fasting insulin level which are higher in 
HD (p < 0.05).8 DM in liver cirrhosis patient can occur 
subclinically because the fasting blood glucose (FBG) 
level in this patient is normal. In this case, patient 
should take the glucose tolerance test to detect the 
impaired glucose tolerance.7
CASE ILLUSTRATION
A 33-year-old female came with chief complaint 
of fatigue since 3 days before admission. Patient 
also complained of nausea, vomiting, and increased 
abdominal circumference since one year ago. Patient 
was diagnosed as DM two months ago by a primary care 
physician on the bases of polydipsia, polyphagia and 
polyuria with elevated capillary blood glucose (CBG) 
of 325 mg/dL. She was given metformin tablet 500mg 
twice daily, however was not compliant to treatment. 
Family history were unremarkable for hepatitis B and 
diabetes. Physical examination showed anemic and 
ascites without stigmata of cirrhosis. Laboratory test 
result showed normocytic normochromic anemia with 
hemoglobin level 6.5 g/dL, mild thrombocytopenia 
with platelet count 185,000/L, low serum iron 7 mg/
dL, normal total iron binding capacity 255 µg/dL, 
normal ferritin 102.38 mg/dL, low serum albumin 2.97 
g/dL, mild increasing of liver enzymes (AST 60 u/L 
and SLT 64 u/L), hyperbilirubinemia (total, indirect 
and direct bilirubin of 1.8 mg/dL, 1.1 mg/dL and 0.7 
respectively), prolonged prothrombin time (PT) 20.3 
seconds, INR of 1.83, creatinine serum 0.5 mg/dL and 
elevated random blood glucose (RBG) 517 mg/dl. 
Serologic test result showed HbsAg positive, HbeAg 
negative, and HBV DNA 1.61 x 104 copy/mL. The 
abdominal ultrasound result showed liver cirrhosis 
with moderate ascites.
Based on clinical findings and laboratory results, 
patient was diagnosed with hepatogenous diabetes 
in liver cirrhosis child B due to chronic hepatitis 
B infection and anemia on chronic disease. The 
patient was treated using restriction of salt and fluids, 
protein 40 g/dL/day, short-acting insulin 3x12 U 
intravenously (IV), long-acting insulin 10 U IV at bed 
time, metformin tablet 500 mg thrice daily per oral, 
spironolactone tablet 100 mg twice daily per oral, 
lamivudine tablet 100 mg once daily per oral. After 
one week therapy, ascites was reduced and hemoglobin 
level, blood glucose, liver enzymes were improved.
Figure 1. Abdominal ultrasonography showed right liver lobe 
cirrhosis with ascites 
DISCUSSION 
Virology test results showed HBsAg positive, 
HBeAg negative, HBV DNA 1.61 x 104 copy/mL. 
There was no doubt that liver cirrhosis in this patient 
was the result of hepatitis B chronic infection (negative 
HBeAg). Progression of liver cirrhosis could be slowed 
down by giving nucleoside analog such as lamivudine. 
Association for the Study of Liver Diseases (AASLD) 
guideline practice recommended antiviral therapy 
for the patient with HBV DNA > 2,000 IU/mL or 
> 104 copy/mL. Treatment recommendation for 
decompensated hepatitis B liver cirrhosis is antiviral 
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drugs. Lamivudine is the first oral agent that is 
considered safe and effective in treating prolonged 
viremia in liver cirrhosis.2,10
In this case, this patient had a history of diabetes 
since 2 months ago. Although it was rare for 33 years 
old patient to have type 2 DM. All of these things 
helped to make sure the diagnosis was diabetic type 
cirrhosis or hepatogeneus diabetes. As the main 
pathogenesis is insulin resistance, patient was treated 
by insulin to regulate the blood glucose and metformin 
to reduce the resistance of insulin. Treating HD can be 
complicated because the liver dysfunction can increase 
response to the treatment by using standard dosage and 
higher risk of side effect if the drugs are metabolized 
in liver. For those reasons, many clinicians use insulin 
as a first line agent in treating diabetic patient with 
liver cirrhosis.4
Ascites occurred because of accumulation of fluid in 
peritoneal cavity as the results of portal hypertension, 
hypoalbuminemia, and hyperaldosteronemia. So, the 
ascites was treated by antialdosteron. Indication for 
albumin use in these cirrhotic patient are spontaneous 
bacterial peritonitis, hepatorenal syndrome, large 
volume of paracentesis, albumin level less than 2.5 g/
dL with complication.11
Viral infection, either acute or chronic, will cause 
anemia of chronic disease. Three major pathophysiology 
of anemia are impaired iron homeostasis, ineffective 
erythropoiesis, reduction of erythropoietin response. 
The normal or raising of ferritin level show increasing 
iron level in red blood cells because of immune 
activation. From the pathologic finding about chronic 
anemia disease, treatment can be done through the 
cure of main disease, use of erythropoietin, or blood 
transfusion.9
Lamivudine, spironolactone, metformin, and 
insulin could control cirrhosis due to hepatitis B, 
hepatogenous diabetes and chronic anemia.
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